-- Days : -- HRS : -- MIN : -- SEC

Register Now →

News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|July 9, 2024

Typical Payer Coverage Criteria for Multiple Sclerosis Therapies

Author(s)Ryan Haumschild, PharmD, MS, MBA, Heidi Crayton, MD , Maria Lopes, MD, MS

Heidi Crayton, MD, discusses the typical coverage criteria requirements she encounters from payers for currently-approved therapies for multiple sclerosis.

Episodes in this series

EP. 1 Teaser: Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis

EP. 1 Teaser: Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis

Video 1 - 3 KOLs are featured in, "Multiple Sclerosis: Impact, Types, Pathophysiology, and Progression"

EP. 2 Multiple Sclerosis: Impact, Types, Pathophysiology, and Progression

Video 2 - 3 KOLs are featured in, "Assessing Limitations, Costs, Mobility and Cognition in Progressive Multiple Sclerosis"

EP. 3 Assessing Limitations, Costs, Mobility and Cognition in Progressive Multiple Sclerosis

3 KOLs in this program

EP. 4 Examining Key Unmet Needs in Multiple Sclerosis

3 KOLs in this program

EP. 5 Patient Satisfaction: Opportunity for Better Multiple Sclerosis Therapies

A panel of 3 experts on multiple sclerosis

EP. 6 MS Treatment Guidelines: Expert Insights on Updates and Decision-Making

A panel of 3 experts on multiple sclerosis

EP. 7 Incorporating a Subcutaneous Novel Therapy into Multiple Sclerosis Treatment

A panel of 3 experts on multiple sclerosis

EP. 8 Examining Challenges with Drug Switching and Step Therapy in MS Treatment

A panel of 3 experts on multiple sclerosis

EP. 9 Typical Payer Coverage Criteria for Multiple Sclerosis Therapies

A panel of 3 experts on multiple sclerosis

EP. 10 BTK Inhibitors' Rationale and Potential Role in Multiple Sclerosis Treatment

A panel of 3 experts on multiple sclerosis

EP. 11 Updates in Recent Clinical Trials in the Treatment of Multiple Sclerosis

A panel of 3 experts on multiple sclerosis

EP. 12 Primary Progressive Multiple Sclerosis Treatment Landscape: Emerging Therapies

A panel of 3 experts on multiple sclerosis

EP. 13 Multiple Sclerosis: Looking Toward the Future

Video content above is prompted by the following questions:

What typical coverage criteria requirements are you seeing from payers with currently-approved therapies for multiple sclerosis (MS)?
Do you see benefit of ICD-10 coding by different MS phenotypes vs. having only one code?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Illustration of neurons - Igor - stock.adobe.com.jpg

Epstein-Barr Virus Link to MS Spurs New Vaccine, T-Cell Trials

BySkylar Jeremias

July 27th 2026

Orange multiple sclerosis awareness ribbon cupped in hands | Image credit: SewcreamStudio - stock.adobe.com

MS Diagnostic Delays Persist, Especially in Under-Resourced Areas

July 22nd 2026

stem cell transplant | Image credit: Vadim - stock.adobe.com

Stem Cell Transplant Outperforms DMTs in Drug-Resistant Relapsing MS

BySkylar Jeremias

July 17th 2026

Neurons illustration | Image credit: Anna - stock.adobe.com

MS Likely Unfolds Along a Continuum Years Before First Symptoms

BySkylar Jeremias

July 15th 2026

Immunoglobulins | Image credit: Dr_Microbe - stock.adobe.com

Ocrelizumab Led to Declines in Immunoglobulins in Patients With MS

ByJulia Bonavitacola

June 30th 2026

Trending on AJMC

FDA Approves Moderna’s mRNA Flu Vaccine After Phase 3 Success

OneOncology Partners With OpenEvidence to Give Physicians Access Within Clinical Workflows

High-Dose Vitamin D3 Fails to Improve PFS in Phase 3 Metastatic CRC Trial

Patients With MASLD Had More Than 2 Times Higher Odds of Eosinophilic Esophagitis Across Age Groups

AHA Proposes Staging System for Pediatric Cardiogenic Shock